A Mouse Skin Multistage Carcinogenesis Model Reflects the Aberrant DNA Methylation Patterns of Human Tumors

Mario F. Fraga,1 Michel Herranz,1 Jesús Espada,1 Esteban Ballestar,1 María F. Paz,1 Santiago Ropero,1 Emel Erkek,2 Onder Bozdogan,2 Héctor Peinado,3 Alain Niveleau,4 Jian-Hua Mao,5 Alan Balmain,5 Amparo Cano,3 and Manel Esteller1

1Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Centre, Madrid, Spain; 2Kirikkale University Faculty of Medicine, Kirikkale, Turkey; 3Departamento de Bioquímica, Facultad de Medicina, Instituto de Investigaciones Biomédicas, Centro de Biología Molecular “Severo Ochoa,” Universidad Autonoma de Madrid, Madrid, Spain; 4Centre Commun de Quantimétrie, Faculté de Médecine, Université Claude Bernard Lyon 1, Lyon, France; and 5Cancer Research Institute, University of California at San Francisco, San Francisco, California

Abstract

Whereas accepted models of tumorigenesis exist for genetic lesions, the timing of epigenetic alterations in cancer is not clearly understood. We have analyzed the profile of aberrations in DNA methylation occurring in cells lines and primary tumors of one of the best-characterized mouse cancerinogenesis systems, the multistage skin cancer progression model. Initial analysis using high-performance capillary electrophoresis and immunolocalization revealed a loss of genomic 5-methylcytosine associated with the degree of tumor aggressiveness. Paradoxically, this occurs in the context of a growing number of hypermethylated CpG islands of tumor suppressor genes at the most malignant stages of carcinogenesis. We have observed this last phenomenon using two approaches, a candidate gene approach, studying genes with well-known methylation-associated silencing in human tumors, and a mouse cDNA microarray expression analysis after treatment with DNA demethylating drugs. The transition from epithelial to spindle cell morphology is particularly associated with major epigenetic alterations, such as E-cadherin methylation, demethylation of the Snail promoter, and a decrease of the global DNA methylation. Analysis of data obtained from the cDNA microarray strategy led to the identification of new genes that undergo methylation-associated silencing and have growth-inhibitory effects, such as the insulin-like growth factor binding protein-3. Most importantly, all of the above genes were also hypermethylated in human cancer cell lines and primary tumors, underlining the value of the mouse skin carcinogenesis model for the study of aberrant DNA methylation events in cancer cells.

Introduction

DNA methylation is the main epigenetic modification in humans. Aberrant DNA methylation has emerged in recent years as a common hallmark of all types of cancer. Two DNA methylation lesions coexist in human neoplasms, hypermethylation of the promoter region of specific tumor suppressor genes within a context of genomic hypomethylation (1–3). It is widely accepted that a succession of cumulative hits occurring in oncogenes and tumor suppressor genes leads to genetic lesions, as represented in the elegant model of the human colon-rectal tumorigenesis proposed by Fearon and Vogelstein (4) in 1990. However, very little is known regarding the precise timetable of epigenetic alterations occurring between the transition of a normal cell through intermediate tumorigenic stages to a tumor cell with invasive properties. To address this issue we have studied how DNA methylation changes progress in a well-established model system of mouse cancerinogenesis, the multistage skin tumor progression model (reviewed in Refs. 5, 6). In this model, beginning with normal mouse skin, sequential topical application of various mutagens, such as the polycyclic aromatic hydrocarbon dimethylbenzanthracene, and tumor promoting agents, such as 12-O-tetra-decanoylphorbol-13-acetate, generate a spectrum of different stages of tumorigenesis ranging from premalignant papilloma to highly metastatic tumors with well-defined genetic lesions in H-ras or p53 (reviewed in Refs. 5, 6). We have examined the aberrant DNA methylation profile (by candidate gene as well as genomic DNA and RNA approaches) of all stages of mouse skin tumor progression, including normal mouse skin; nontumorigenic and tumorigenic immortalized keratinocytes (MCA3D and PAM212, respectively; Refs. 7, 8); benign papilloma cells (PB and MSCP6; Refs. 9, 10); tumorigenic squamous carcinoma cells representative of different degrees of differentiation, invasion, and metastasis (PDV, MSCP1B9, and HaCa4; Refs. 11–13); and highly ana-plastic spindle carcinoma cell lines displaying metastatic behavior (MSC11A5, CarB, and CarC; Refs. 13, 14). Aberrantly methylated genes identified by the mouse study were confirmed in human neoplasms to evaluate the potential of this system to find clinically relevant genes with methylation-associated inactivation and also its ability to serve as a tool to improve understanding of the timing and hierarchy of epigenetic lesions in human cancer.

Materials and Methods

Mouse and Human Tumorigenic Cell Lines and Primary Tumors. The generation and culture conditions of the cell lines from the mouse skin multistage tumor progression model have been described previously (7–14). According to an increasing order of tumorigenic activity, they included MCA3D (8, 11); PB and MSCP6 (9, 10); PDV (8, 11); PAM212 (7); MSC11B9 and MSC11A5 (13, 14); HaCa4 (12); and CarB and CarC (13, 14). Thirty human cancer cell lines corresponding to 14 cell types were obtained from the American Type Culture Collection (Rockville, MD) and the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). Demethylating treatments were carried out using 5-aza-2-deoxycytidine (5 µM) for 48 h, with drug and medium replaced 24 h after the beginning of the treatment. Tissue samples of 86 human primary malignancies corresponding to colon, breast, lung, and head-neck carcinomas; glioma; and leukemia were also obtained at the time of clinically indicated surgical procedures, and DNA was extracted according to standard procedures. Finally, 15 primary mouse skin tumors (5 papillomas, 5 squamous carcinomas, and 5 spindle carcinomas) from the same genetic background were obtained.

Genome Content of 5-Methylcytosine. Quantification of the degree of methylation was carried out by high-performance capillary electrophoresis as described previously (15, 16). In brief, DNA samples (5 µL, 0.2–1 µg/µL) were enzymatically hydrolyzed with nuclease P1 (Sigma-Aldrich Quimica S.A.,...
EPIGENETICS OF SKIN CANCER

Madrid, Spain) and alkaline phosphatase (Sigma-Aldrich Química S.A.). Samples were directly injected in a high-performance capillary electrophoresis system (P/ACE MDQ; Beckman-Coulter S.A., Madrid, Spain) connected to a data-processing-station (32 Karat Software) and using an uncoated fused-silica capillary (Beckman-Coulter S.A.: 60.2 cm × 75 μm, effective length 50 cm). The running buffer was 14 mM NaHCO₃ (pH 9.6) containing 20 mM SDS. Running conditions were 25°C and operating voltages of 17 kV. All of the samples were analyzed in duplicate, and three analytical measurements were made per replicate. Quantification of the relative methylation of each DNA sample was determined as the percentage of mC of total cytosines: mC peak area × 100/(C peak area + mC peak area).

**Immunolocalization of 5mC.** Cells grown on coverslips were stained with mouse monoclonal antibodies against 5mC (kindly provided by Alain Niveleau, Université Claude Bernard, Lyon, France) as described previously (17). Images of the nuclear immunolocalization of 5mC were obtained in a Leica DMRA fluorescence microscope coupled to a Leica DC200 digital camera and captured with the Adobe Photoshop software. Densitometric profiles of light intensity through the orthogonal projections in the XY plane of captured images were generated by the public NIH Image software. Profiles are representative of the analysis of ~50 different nuclei in three different samples. To avoid false light signals of fluorescence stacking due to an artifactual morphology, only nuclei with a homogeneous chromatin distribution revealed after 4’,6-diamidino-2-phenylindole staining were considered in the densitometric analysis.

**DNA Methylation Analysis of Particular Genes.** We carried out bisulfite modification of genomic DNA as described previously (18). We established methylation status by PCR analysis of bisulfite-modified genomic DNA using two procedures. Firstly, all of the genes investigated were analyzed by bisulfite genomic sequencing of their corresponding CpG islands, as described elsewhere (19). Both strands were sequenced. The second analysis used methylation-specific PCR for all of the genes analyzed in several cancer cell lines and tissue samples, as described previously (18). We designed all of the bisulfite genomic sequencing and methylation-specific PCR primers according to genomic sequences around presumed transcription start sites of investigated genes. Primer sequences and PCR conditions for methylation analysis are included in supplementary web data.

**Chromatin Immunoprecipitation.** Chromatin immunoprecipitation assays were performed as described previously (19) using commercial antiacetylated histone H4 and antimethylH3 antibodies (Upstate Biotechnologies). Chromatin was sheared to an average length of 0.25–1 kb for this analysis. PCR amplification was performed in 25 μl with specific primers for each of the analyzed promoters. For each promoter, the sensitivity of PCR amplification was evaluated on serial dilutions of total DNA collected after sonication (input fraction). Primer sequences were included in Supplemental Data.

**Mouse cDNA Microarray.** A cDNA microarray containing the National Institute on Aging/NIH Mouse 15k cDNA clone set⁶ was used. Briefly, the mouse cDNA microarray consists of ~15,000 unique cDNA clones (rearrayed among 52,374 expressed sequence tags from pre- and peri-implantation embryos, E12.5 female gonad/mesonephros, and newborn ovary) and ~50% novel genes with an average insert size of ~1.5 kb (20). Slides were scanned for Cy3 and Cy5 fluorescence using Scanarray 5000 XL (GSI Lumonics, Kanata, Ontario, Canada) and quantified using the GenePix Pro 4.0 software (Axon Instruments Inc., Union City, CA), Genes were selected to be up-regulated or down-regulated if the difference in ratio was at least 2-fold. For clustering analysis, the SOTA clustering program⁷ was used, and trees were viewed using the TreeView program.

**Semi-quantitative Reverse Transcription-PCR Expression Analysis.** We reverse-transcribed total RNA (2 μg) treated with DNase I (Ambion) using oligo(dT)₁₂–₁₅ Primer with Superscript II reverse transcriptase (Life Technologies, Inc.). We used 100 ng of cDNA for PCR amplification, and we amplified all of the genes with multiple cycle numbers (20–35 cycles) to determine the appropriate conditions for obtaining semi-quantitative differences in their expression levels. Reverse transcription-PCR primers were designed between different exons to avoid any amplification of DNA. We also carried out PCR with β-actin (25 and 28 cycles) to ensure cDNA quality and loading accuracy. Primer sequences are included in Supplemental Data.

**Western Blot.** Cells were harvested by centrifugation, and cell pellets were resuspended in ice-cold buffer [50 mM Tris-Cl (pH 8), 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, and 0.1% SDS] with protease inhibitors (phenylmethylsulfonyl fluoride, leupeptin, aprotinin, and pepstatin) and incubated on ice for 5 min. One hundred μg of total cellular extract was fractionated on a 10% SDS-PAGE gel, transferred to polyvinylidene difluoride membrane (phenylmethylsulfonyl fluoride; Immobilon-P; Millipore), blocked in 10% milk in Tris buffered saline (pH 7.5) with 0.1% Tween 20 and immunoprobed with Dnm1 (1:500), Dnm3a (1:1000), and Dnm3b (1:1000) antibodies (Abcam, Cambridge, United Kingdom). Horseradish peroxidase-conjugated antirabbit IgG (Amersham, Buckinghamshire, United Kingdom) at a dilution 1:3000 in [Tris buffered saline (pH 7.5) with 0.1% Tween 20] was used as the secondary antibody and β-actin (Sigma) as loading control. The signals were detected with Luminol reagent detection kit (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).

**Transfection Experiments and Colony Formation Assays.** Transfections and colony assays were developed as described previously (19). In brief, pSV-β-galactosidase control vector and the expression vectors for the IGFBP3 (pDNA-3 HIGFBP3-3, provided by Dr. Sylvie Babajko, Hopital Saint Antoine, Paris, France) and the CSR2P genes (pCMV5-NA-CHRP2, provided by Dr. Axel M. Gressner, University of Aachen, Aachen, Germany), also containing neomycin resistance genes, were transfected into the T47D and HCT-116 cells, respectively, by the lipofection method. Cells were seeded in a six-well plate a day before transfection at a density of 2 × 10⁴ cells/well. Two μg of purified plasmid DNA were transfected with LipofectAnmine Plus reagent, according to the manufacturer’s recommendations. The experiment was repeated three times. 24 h after transfection, β-galactosidase activity was measured in the cells carrying the control vector using a β-galactoside activity kit. Clones expressing the transfected proteins were selected in complete medium supplemented with 1 mg/ml G418, 48 h after transfection. Stable clones were maintained in complete medium with G418 (800 μg/ml). Total RNA from individual clones was extracted, and reverse transcription-PCR was performed to confirm that the clones were expressing the transfected genes. T47D and HCT-116 cells were also transfected with the vector containing no inserts and stable clones isolated. After ~16 days of selection, stable G418-resistant colonies were fixed, stained with 2% methylene blue in 60% methanol, and the average number of colonies present in each well was counted. Wild-type p53 (pWZL- hp53 wt, Hygro) and p16INK4a (pLPC-hp16 wt-HA-puro) were used as additional positive controls, and mutants p53 (pWZL-hp53-N175H, Hygro) and p16INK4a (pLPC-hp16 mut-HA-M53I-puro) were used as negative controls. All of the p53 and p16INK4a expression vectors were provided by Dr. Manuel Serrano.

**Results**

**5-Methylcytosine DNA Content in Cancer Cell Lines and Primary Tumors of the Mouse Skin Tumor Progression Model.** It is accepted that the majority of human tumors have a diminished 5-methylcytosine DNA content when compared with normal tissue counterparts (21, 22). Here, we studied the alterations in the overall DNA methylation status in the mouse skin model of multistage carcinogenesis to determine when these changes also occur during tumor progression. We used two complementary approaches, high performance capillary electrophoresis, an analytical technique that provides an absolute measurement of 5-methylcytosine content (15, 16), and immunolocalization of 5-methylcytosine to give qualitative information on nuclear distribution (17, 23).

High-performance capillary electrophoresis analysis showed that there is a loss of 5-methylcytosine during tumor progression (Fig. 1A). There are two decreases visible in the 5-methylcytosine content during tumor progression: the first one occurs in the transition from nonmalignant (MCA3D cells) to benign papilloma cells (PB and MSCP6) with a loss of 25% of the total 5-methylcytosine content. The second important hypomethylation event represented a loss of more than half (54%) of the total 5-methylcytosine genomic content; most importantly, this drop occurs when the transformed cells undergo an epithelial (MSC11B9 cells) to spindle (MSC11A5 cells) transition in...
cancer cell lines as a percentage of the total cytosine pool. Results are expressed as mean; bars, ±SD. B, measurement of 5dmC content by high-performance capillary electrophoresis in mouse skin primary tumors (papillomas, n = 5; squamous carcinomas, n = 5; and spindle carcinomas, n = 5) as a percentage of the total cytosine pool (right). Results are expressed as mean; bars, ±SD. NS, normal mouse skin.

their phenotype. This morphological change is associated with a striking increase in tumorigenicity, the underlying cause of which remains unresolved.

Loss of 5-methylcytosine during the multistage carcinogenic process was also demonstrated by immunolocalization experiments. A high correlation between 5-methylcytosine levels determined by either high-performance capillary electrophoresis or immunolocalization was also observed. Interestingly, immunostaining demonstrated that the loss of 5-methylcytosine was not homogeneous within the nucleus, which is in agreement with data published previously (23).

To determine whether global DNA methylation changes observed in the cell lines of the tumor progression model could be extrapolated to primary tumors, we analyzed by high-performance capillary electrophoresis the 5-methylcytosine content of a series of primary mouse papillomas, squamous carcinomas, and spindle carcinomas (Fig. 1B). The data demonstrated that these skin primary tumors were hypomethylated at their DNA when compared with the normal skin. In addition, the most hypomethylated tumors were those presenting the most aggressive behavior, spindle carcinomas, in a close resemblance to our findings in the cancer cell lines. Very little decrease in methylation was detected in the primary papillomas in contrast to the results from the cell lines, but this may be due to the fact these are contaminated by stromal cells or inflammatory cells, reducing the apparent total amount of demethylation. The more cellular squamous and spindle carcinomas, however, showed a clear decrease in 5-methylcytosine content.

Analysis of Methylation-Associated Silencing of Candidate Tumor Suppressor Genes in Mouse Skin Cancer Cell Lines. To define a profile of tumor suppressor genes with methylation-associated silencing in the multistage mouse skin progression model, we analyzed the methylation status of the promoter-associated CpG island of six genes known to be hypermethylated in human cancer (1–3). These were the DNA repair genes MLH1, BRCA1, and MGMT (O6-methylguanine DNA methyltransferase), the cellular adhesion-related gene E-cadherin, the transcriptional repressor Snail, and the Snail/Gfi-1 repressor family member (MLT1). The DNA methylation patterns were characterized by bisulfite genomic sequencing and methylation-specific PCR. Four of these genes (MGMT, Snail, E-cadherin, and MLT1) were found methylated in the mouse skin carcinogenesis model (Table 1). Methylation of the promoter regions was always associated with transcriptional silencing, and expression could be restored with the use of the demethylating agent 5-aza-2-deoxycytidine. An illustrative example of the DNA methylation and expression analysis developed is shown in Fig. 2.

Three of the four genes identified as methylated (MGMT, MLT1, and Snail) underwent hypermethylation at the beginning of the carcinogenic process, during the transition from fresh normal skin to immortalized nontumorigenic keratinocytes (MCA3D; Table 1). Thus, CpG island hypermethylation of candidate tumor suppressor genes is an early event in tumorigenesis.

In contrast, E-cadherin hypermethylation occurred in the latter stages of tumor progression coinciding with loss of epithelial phenotype (Table 1). Hypermethylation-associated silencing of E-cadherin is found in human tumors (1–3), but loss of E-cadherin expression can also result from the activity of the transcriptional repressor Snail (24). The Snail gene was also found to undergo epigenetic inactivation but in a different context to that of the E-cadherin promoter. During early stages of tumorigenesis the E-cadherin and Snail CpG islands are unmethylated and hypermethylated, respectively. However, when the transition from an epithelial (MSC11B9) to spindle (MSC11A5) or dedifferentiated (HaCa4) phenotype occurs, the E-cadherin promoter becomes hypermethylated, whereas the Snail island undergoes demethylation (Table 1). For both genes, CpG island hypermethylation

<table>
<thead>
<tr>
<th>Table 1</th>
<th>CpG island methylation status of candidate genes in cancer cell lines from the mouse skin tumor progression model</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NS</td>
</tr>
<tr>
<td>BRCA1</td>
<td>U</td>
</tr>
<tr>
<td>MLH1</td>
<td>U</td>
</tr>
<tr>
<td>MGMT</td>
<td>U</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>U</td>
</tr>
<tr>
<td>Snail</td>
<td>U</td>
</tr>
<tr>
<td>MLT1</td>
<td>U</td>
</tr>
</tbody>
</table>

Abbreviations: NS, normal skin; M, methylated; U, unmethylated.
was always associated with gene silencing, and expression was restored with 5-aza-2-deoxycytidine treatment as described previously.

Histone Modifications and Expression of DNA Methyltransferases in the Mouse Skin Cancer Model. Modifications in the histone tails (acetylation and methylation among others), the denominated histone code, are key in determining the active or silenced state of any given gene (25). To assess the histone modification status of the methylated and unmethylated genes analyzed in the mouse skin carcinogenesis model, we performed chromatin immunoprecipitation analysis with antibodies raised against acetylated histone H4 and dimethylated lysine 4 histone H3, both modifications associated with transcriptional activation.

We observed a loss of both acetylated histone H4 and dimethylated lysine 4 histone H3 within all of the hypermethylated CpG island promoters, whereas for both, modifications showed a significant enrichment in unmethylated CpG islands. For instance, the MLH1 promoter, which is unmethylated and actively transcribed in all of the cell lines, was found to be associated with high amounts of both acetylated histone H4 and dimethylated lysine 4 histone H3 (Fig. 3A). The scenario for E-cadherin and Snail, however, was more dynamic: in the PAM212 cell line an unmethylated CpG island for E-cadherin was associated with enhanced amounts of acetylated histone H4 and dimethylated lysine 4 histone H3 and active transcription, whereas in CarB and CarC cells a fall of both histone modifications was associated with CpG island hypermethylation and silencing (Fig. 3A). For Snail the converse pattern was observed: methylation of the island, loss of acetylated histone H4 and dimethylated lysine 4 histone H3 and silencing in PAM212, and an unmethylated CpG island with increased acetylated histone H4 and dimethylated lysine 4 histone H3 and active transcription in CarB and CarC cells.

We then sought to determine the pattern of expression of the DNA methyltransferases (Fig. 3B) throughout the progression model. The expression of DNA methyltransferase 1 and DNA methyltransferase 3b was studied by Western blot using nuclear extracts obtained from cells across the spectrum of different mouse skin carcinogenesis stages. We found elevated levels of both DNA methyltransferases from early to late stages of tumorigenesis. For example, the highly metastatic cell line CarC had a 4-fold increase in DNA methyltransferase 1 and DNA methyltransferase 3b compared with just the immortalized MDA3D cells, whereas intermediate stages (such as PAM212 cell line) also had intermediate levels of DNA methyltransferase 1/3b protein (2-fold increase versus MDA3D; Fig. 3B).

![Fig. 2](image-url)

**Fig. 2.** CpG island methylation-associated silencing of candidate genes in the mouse tumor progression. A, schematic representation of the E-cadherin CpG island, where ● indicate methylated CpGs and ○ unmethylated CpGs. The black arrows indicate the position of the transcription start site. B, illustrative methylation-specific PCR analyses for the CpG island methylation status of the E-cadherin, MLH1, and MGMT genes. The presence of a PCR band under the U or M lane indicates unmethylated or methylated alleles, respectively. In vitro methylated DNA (IVD), used as positive methylated control and normal skin (NS), used as unmethylated control. C, examples of the reverse transcription-PCR analysis for basal gene expression and reactivation after treatment with a demethylating agent. Restoration of E-cadherin and MGMT gene expression is observed in the hypermethylated cell lines CarB and CarC after treatment with 5-aza-2-deoxycytidine. β-Actin expression is shown as an internal control.

![Fig. 3](image-url)

**Fig. 3.** Pattern of histone modifications and expression of DNA methyltransferases (DNMT) in the mouse skin tumorigenesis model. A, chromatin immunoprecipitation analysis of the histone modification status of the MLH1 and E-cadherin promoters. The unbound (UB) and bound (B) fractions of each chromatin immunoprecipitation experiment are shown. Each graph shows the B:UB ratio for each studied promoter. In the cell line PAM212 an unmethylated promoter of E-cadherin is enriched in acetylated histone H4 and methyl-K4-H3, both markers of active transcription, whereas in the E-cadherin methylated cell lines CarB and CarC both markers are depleted. B, Western blot analysis for DNMT1 and DNMT3b expression in MCA3D, PAM212, CarB, and CarC cell lines; bars, ±SD.
Thus, CpG island hypermethylation of tumor suppressor genes is not an isolated phenomenon in the epigenetics of cancer progression, because it occurs in a context of disturbance in the histone and DNA methylation machinery.

Identification of Methyl-Targeted Genes by DNA Demethylating Treatment and Mouse cDNA Microarray Analysis. To obtain a global view of the number of genes epigenetically silenced throughout the different stages of mouse skin tumorigenesis, we hybridized differentially labeled RNA from each untreated cell line versus the same cell line after treatment with 5-aza-2-deoxycytidine to a mouse cDNA microarray containing 15,000 clones. The efficiency of the demethylating treatment was measured by the determination of the 5-methylcytosine content by high-performance capillary electrophoresis (15, 16) and by the reactivation of the methylation-associated genes as described above. This is described in the flowchart in Fig. 4A.

cDNA microarray expression analysis showed that after treatment with 5-aza-2-deoxycytidine, the cell lines representing early stages of carcinogenesis such as MCA3D or PAM212 show a reactivation of 2.1% and 2.4% of genes, respectively, whereas those representative of advanced stages, such as CarB and CarC, had a restoration of expression of 4.6% and 5.8% genes, respectively (Fig. 4B). Clustering analysis of the pattern of expression after demethylation treatment also yielded a profile that allowed discrimination between early (MCA3D and PAM212) and advanced (CarB and CarC) tumorigenesis (Fig. 4C).

Analysis of the expression microarray data revealed 86 candidate sequences with a more than 3-fold increase after treatment with 5-aza-2-deoxycytidine (Fig. 4A). From these clones, 18 genes with putative tumor suppressor-like activities were selected, 10 of which contained a CpG island within their promoter region. We analyzed the possible methylation-associated silencing of four genes from this group: the gene encoding the LIM domain protein CRP2 molecular adapter (CSR2P; Ref. 26), the insulin-like growth factor binding protein-3 (IGFBP3; Ref. 27), the chemokine receptor CMKAR4 (28), and the antioxidant enzyme peroxiredoxin-1 (PRDX1; Ref. 29). CpG island hypermethylation was found to be present in the promoters of IGFBP3, CMKAR4, and PRDX1 genes at different stages of the mouse skin carcinogenesis model, in both cancer cell lines and primary tumors (Table 2; Supplemental Data). Hypermethylation of CSR2P was only found in 1 of 10 mouse skin tumor cell lines. The presence of promoter hypermethylation was associated with transcriptional repression in all of the cases, which was relieved by the use of 5-aza-2-deoxycytidine. The representative detailed methylation and expression analysis for the IGFBP3 gene is shown as an example in Fig. 4D.
The Aberrant DNA Methylation Pattern Observed in Mouse is Mimicked by Human Nonmelanoma Skin Cancer. We used first an equivalent cell line progression model in humans to the mouse skin multistage, consisting in three different stages of nonmelanoma human skin cancer: normal skin, immortal nontumorigenic human keratinocytes (HaCaT; Ref. 30), and high-grade malignant human epidermoid carcinoma cells (A431; Ref. 31). Similarly to the mouse, we found an increased loss of 5-methylcytosine DNA genomic content associated with the increased tumorigenic activity: HaCaT showed a 15% reduction of 5-methylcytosine DNA content versus the normal skin, whereas the aggressive cell line A431 displayed a 25% drop.

Related to CpG island methylation, we studied the methylation status of the four new identified methylation-positive genes in the mouse model (CSRP2, IGFBP3, CMKAR4, and PRDX1) in these three human skin samples. The last three genes were found hypermethylated in the nonmelanoma skin cancer cell line A431, whereas all four were unmethylated in normal skin and nontumorigenic keratinocytes. CSRP2 was found unmethylated in A431. Most important, the presence of aberrant CpG island methylation was not a cell culture phenomena, because we found CpG island promoter hypermethylation of these genes in a significant proportion, from 58% to 12%, of primary nonmelanoma human skin tumors (n = 26; Table 2).

Methylation-Associated Silencing Outside Skin Tumors. To obtain a comprehensive view of the relevance of the methylation status of CSRP2, IGFBP3, CMKAR4, and PRDX1 outside skin tumors, we screened a large panel of cancer cell lines (Table 2; Supplemental Data). In all of the cases, the presence of methylation was associated with gene silencing, and reactivation by 5-aza-2-deoxycytidine was demonstrated. The illustrative case for CSRP2 with bisulfite genomic sequencing, methylation-specific PCR analysis and expression study is shown in Fig. 5. CpG island promoter hypermethylation of IGFBP3 was the most common event, being present in 60% (17 of 28) of cancer cell lines from different cell types (Table 2).

We tested the relevance of these aberrant methylation lesions not only in vitro cultured cancer cells but also in vivo in samples taken from cancer patients. For this purpose we analyzed the CpG island methylation status of the four selected candidate genes (CSRP2, IGFBP3, CMKAR4, and PRDX1) in human primary tumors (n = 83), including all of the major common cell types (breast, colon, lung, brain, head and neck cancer, and leukemia; Table 2; Supplemental Data). CSRP2, IGFBP3, CMKAR4, and PRDX1 were found significantly hypermethylated across the spectrum of primary tumors. From a quantitative standpoint, IGFBP3 CpG island hypermethylation was the most common epigenetic alteration, similar to the cell lines, being found in 57% (37 of 65) of all of the primary malignancies (Table 2). Most interesting, a tumor type-specific profile was observed, for example the chemokine inhibitor CMKAR4 was methylated in leukemia but not in mammary or colon tumors (Supplemental Data).

<table>
<thead>
<tr>
<th>Table 2 Percentage of CpG island hypermethylation in mouse and human cancer samples for the identified new target genes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mouse</strong></td>
</tr>
<tr>
<td><strong>Mouse skin tumor cell lines (n = 10)</strong></td>
</tr>
<tr>
<td>CSRP2</td>
</tr>
<tr>
<td>3/10 (30%)</td>
</tr>
<tr>
<td>8/10 (80%)</td>
</tr>
<tr>
<td>3/10 (30%)</td>
</tr>
<tr>
<td><strong>Growth-Inhibitory Effects in Human Cancer Cells.</strong> Finally, to gain additional insight into the potential role and relevance of these hypermethylated genes for tumor formation, we reintroduced CSRP2 and IGFBP3 in the human breast and colorectal cancer cell lines T47D and HCT-116, respectively, in which we had demonstrated inactivation by hypermethylation. Overexpressing a previously silenced gene product to measure the tumor suppressing-like activity has been successfully applied recently to other methylation-silenced genes, such as SEMA3B, SOCS-1, or CRIP1 (32–34). After selection...</td>
</tr>
</tbody>
</table>
of drug-resistant colonies and the demonstration that each gene was re-expressed, we found that the genetic restoration of any of these genes was sufficient to significantly decrease colony formation, 80% for CSRP2 and 90% for IGFBP3, as did our positive control p53 (95% reduction) or p16INK4a (90% reduction), but not in the case of the mutant p53 or p16INK4a forms or the empty vectors. A representative experiment for CSRP2 is shown in Fig. 5D.

**Discussion**

In the genesis and progression of cancer an interplay between genetic and environmental factors occurs. Epigenetics, understood as a mechanism of conferring heritable states of gene expression without altering the DNA sequence, is now established as an important factor in tumorigenesis, largely represented by DNA methylation and histone modifications. Although CpG island hypermethylation-associated silencing of tumor suppressor genes (BRCA1, MLH1, and so forth) and global genomic hypomethylation are accepted as playing a fundamental role in cancer we are still in the early stages of understanding the timing and hierarchy of epigenetic lesions and their cross-talk with genetic and environmental factors. We have defined the DNA methylation status of a well-known carcinogenic system, the mouse skin multistage progression model (7–14), and demonstrated the cumulative appearance of aberrant DNA methylation and its lesions.

It is clear that the genome-wide loss of 5-methylcytosine is a molecular hallmark associated with the acquisition of a transformed phenotype. The first decrease in overall 5-methylcytosine levels was seen during the early stages of benign tumor growth. A second, more precipitous drop occurred when the cancer cells changed from an epithelial phenotype to a highly metastatic dedifferentiated/spindle morphology. These data support the use of genomic hypomethylation levels as a biomarker of tumor aggressiveness. These results confirm that global genomic hypomethylation does not exist as a static predefined value throughout the process of carcinogenesis but rather as a dynamic parameter. Our data, together with recent experiments showing an enhanced tumorigenicity and chromosomal instability in the mouse with hypomorphic alleles of the DNA methyltransferases (35), suggests an important role for DNA hypomethylation in malignant transformation.

Cancer epigenetics studies cannot be fully understood if we do not determine the relevance of the silencing of tumor suppressor genes associated with CpG island hypermethylation and its histone modifications and chromatin-linked changes. In this study, using candidate gene and demethylating microarray expression approaches, we have shown that cancer cells accumulate methylation-mediated gene silencing from the early to the advanced carcinogenic stages. Whereas normal skin (or any other normal tissue) presents unmethylated CpG islands, the earliest step in the process, when we just established methylation-associated silencing at the early stages of tumorigenesis was so that it had methylation-associated silencing at the early stages. The dynamics of Snail CpG island methylation is also in strict agreement with its expression pattern during mouse skin tumor progression (24). Furthermore, Snail recruits histone deacetylase activity to the E-cadherin promoter (39), which, in turn, associates with DNA methyltransferases. Therefore, the epigenetic reactivation of Snail in late stages of tumorigenesis may promote the hypermethylation of the E-cadherin CpG island and lead to full silencing in an example of cross-talk between epigenetic events.

At this point it is important to stress the relevance of the multistage mouse skin carcinogenesis model (reviewed in Refs. 5, 6) as a tool for a better understanding human cancer epigenetics and assisting the development of new anticancer agents. First, genes with known methylation-associated silencing in human tumors (MGMT, E-cadherin, and so forth) were also found epigenetically inactive in the mouse tumors. Secondly, microarray analysis of mouse cancer cells treated with demethylating agents revealed new set of genes with not only methylation-associated silencing in mouse tumors but also in human primary cancer. These target genes include, among others, the insulin-like growth factor binding protein 3 (IGFBP3), a mediator of apoptosis with antiproliferative signaling effect (27); the chemokine receptor CMKAR4, implicated in tumor adhesion to microvascular endothelial cells (28); the 1-Cys peroxiredoxin (PRDX1), involved in the defense against oxidant stress (29); or the cell differentiating factor cystein-rich protein 2 (CSRP2; Ref. 26). An evaluation of the tumor suppressor-like activities of these genes has just begun, and mutation screening of these genes in cancer cells is reported in the literature, but each one will merit a more profound study to establish their contribution to tumorigenesis and their potential as biomarkers of the disease.

Finally, similar epigenetic behavior observed in multistage skin tumor progression compared with human cancer cell lines and both mouse and human primary tumors may herald the mouse model as an excellent system to test all current and newly produced anticancer drugs targeting epigenetics (reviewed in Ref. 3). We are in the early stages of the development of DNA demethylating drugs and inhibitors of histone deacetylases for the treatment of cancer, although clinical studies using these agents have been initiated worldwide. The versatility of the mouse carcinogenesis model now offers a safe and convenient environment to test these compounds for clinical efficacy and toxic side effects.

**References**


A Mouse Skin Multistage Carcinogenesis Model Reflects the Aberrant DNA Methylation Patterns of Human Tumors

Mario F. Fraga, Michel Herranz, Jesús Espada, et al.

*Cancer Res* 2004;64:5527-5534.